JS401
/ Shanghai Junshi Biosci, Risen (Suzhou) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 18, 2023
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401
(clinicaltrials.gov)
- P1 | N=44 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.
New P1 trial • Dyslipidemia • Hypertriglyceridemia • ANGPTL3 • APOA1 • APOB
1 to 1
Of
1
Go to page
1